CliffBio
biologic

Thrombin-Jmi, Thrombocoll

Thrombin, Topical (Bovine)

Loss of exclusivityApril 2038projected — 12-year biologic exclusivity estimate
CompanyGenTrac, Inc.

Drug detail

Brand nameThrombin-Jmi, Thrombocoll
Active ingredientThrombin, Topical (Bovine)
Strength5,000IU
Dosage formSolution
RouteTopical
ModalityBiologic
FDA approvalApril 2026
Marketing statusRx

More from GenTrac, Inc.

Source: FDA Purple Book, layered on the CliffBio company graph. Cliff dates are the projected — 12-year biologic exclusivity estimate; estimates are projections, not legal advice.

Thrombin-Jmi, Thrombocoll patent cliff — loss of exclusivity April 2038 | CliffBio